Statins induce lethal effects in acute myeloblastic lymphoma cells within 72 hours by Burke, Lillian P. & Kukoly, Cynthia A.
ORIGINAL ARTICLE: RESEARCH
Statins induce lethal effects in acute myeloblastic lymphoma cells within
72 hours
LILLIAN P. BURKE & CYNTHIA A. KUKOLY
Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, USA
(Received 24 July 2007; revised 9 October 2007; accepted 17 October 2007)
Abstract
HMG-CoA Reductase inhibitors (statins) induce apoptosis in acute myeloid leukemia (AML) cells in vitro; however, the
concentrations associated with cell death in AML cells are higher than those clinically tolerated during prolonged therapy.
We therefore wished to determine whether short exposures to lovastatin might induce cell death in AML cells at clinically
attainable concentrations. The time and concentration dependence of HL60 and U937 cells was determined and showed that
cell death was delayed. IC50 values and IC90 values determined on day 6 suggested that the sensitivity of AML cells to statins
may occur at lower concentrations than previously reported. After 72 h, mevalonate did not rescue AML cells from cytotoxic
concentrations of statins, suggesting that, although cell death was delayed, lovastatin induced lethal effects within 72 h. In
conjunction with previously reported Phase I studies, the data presented here suggest that the high-dose, short course statins
may be useful for the treatment of patients with AML.
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Introduction
Statins are useful for the treatment of patients with
hypercholesteremia and are among the most widely
prescribed drugs. Meta-analyses suggest that statin
treatment may decrease the risk of developing certain
malignancies although recent studies have provided
data conflicting with this hypothesis [1,2]. In vitro,
statins induce apoptosis in both primary cells and in
tumor cells derived from patients with a variety of
malignancies [3]. Sensitivity to statin-induced cyto-
toxicity is tumor-line specific. Sensitive cells include
cells derived from AML, including chemotherapy-
resistant AML [4], as compared with the relative
statin resistance seen in cells derived from patients
with acute lymphoid leukemia [5,6]. Drug resistant
cells may be more sensitive to statins than the non-
drug resistant cells, suggesting that statins may be
useful for the treatment of drug-resistant malignan-
cies [4,7 – 9].
Statins induce cell death in malignant cells at
concentrations that are significantly higher than those
that are effective for the treatment of hypercholester-
emia [10]. Cell death occurs via apoptosis and
lovastatin concentrations of up to 5 mM and are
required to induce apoptosis in AML cell lines and in
primary AML cells [5,11,12]. Six of 7 AML cell lines
had an IC50 of 5.3 mM when exposed to statins for
2 days [5,13]. Primary AML cells also showed a
decrease in proliferation and in colony formation
when exposed to statins for 2 days, although several of
the cultures required lovastatin concentrations of up
to 40 mMormore to effect a decrease prolification and
or colony formation. In contrast, normal hematopoie-
tic cells are tolerant of lovastatin or atorvastatin
concentrations of up to 160 mM or more [5,14,15].
These laboratory findings suggest that lovastatin
concentrations of approximately 5 mM or more
might be required to induce cell death in AML cells.
Unfortunately, this lovastatin concentration is at the
upper limits of tolerability in human studies, except
when the duration of exposure is limited to four
days or less [16]. Although several animal species
tolerate prolonged duration of statin exposure at
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concentrations of 2 – 4 mM [15,17], humans do not
tolerate drug concentrations in this range for more
than 4 – 7 days. In a Phase I study of lovastatin, given
at up to 25 – 45 mg/kg/day for 7 days, the peak
lovastatin concentration in any patient was reported
as 3.9 mM [18]. At higher lovastatin concentrations,
or with more prolonged duration of therapy, non-
hematological toxicities, such as myopathy, hepato-
toxicity and renal failure are dose limiting [19]. In
contrast, when the lovastatin exposure was limited to
a 4 day course of treatment, peak concentrations of
up to 12 mM were tolerated without evidence of
clinical toxicity [16]. Taken together, these studies
suggest that patients might tolerate lovastatin con-
centrations of up to 12 mM, or possibly more, if the
duration of statin exposure is limited to 4 days or
less.
However, it is not known whether short courses of
high concentrations of statins would be therapeuti-
cally efficacious. As a first step in examining these
questions, we sought to determine the time and
concentration dependence of statin-induced cyto-
toxicity for AML cell lines in order to determine the
optimal duration of statin exposure for clinical
studies in patients with AML. The results reported
here support the development of clinical trials of
short-course, high dose statins for the treatment of
AML.
Materials and methods
Cell lines
Cell lines used were obtained from ATCC (Mana-
ssas, VA; HL60 and U937 cells). Cells were grown in
RPMI 1640 (Gibco, Carlsbad, CA, #11875 – 093)
with 10 mM Hepes and 1 mM sodium pyruvate,
supplemented with 10% fetal calf serum (FCS,
Hyclone, Logan, UT). All cell lines were maintained
at 378C in a humidified atmosphere with 5% CO2.
Reagents
Mevalonate was obtained as mevalonolactone (Sig-
ma, St. Louis, MO M4667). Stock concentrations
were made in DMSO and later diluted in media or
PBS prior to use in culture. Lovastatin was obtained
from CalBiochem, (San Diego, CA), and was
converted to the open acid form prior to use as
described by Hancock [20]. The resulting lyophilized
statins were resuspended in DMSO (Dimethyl
sulfoxide, Catalog # D8418, Sigma, St. Louis,
MO) and stored in small aliquots at 7208C until
time of use. DMSO at the highest concentration used
for the lovastatin treatment served as the vehicle
control.
Cell proliferation
‘‘MTS assay’’: Cells were seeded in 96 well flat-
bottomed plates (100 mL/well, Falcon). For all
assays, we determined the number of cells to be
plated so that the control cells would be experiencing
log phase growth and would be at a concentration so
that the assay was in the linear portion of the
absorbance curve on the assay (typically 3000 cells/
well). Cell proliferation assays to determine IC50
concentrations were measured using the MTS-based
assay by Promega (Cell Titer96 Aqueous One
Solution, Madison, WI), according to the manufac-
turer’s instructions. All samples were run in triplicate
and absorbance recorded at 490 nm with a plate
reader after incubation at 378C for 1 – 3 h. Back-
ground absorbance was corrected by subtracting the
absorbance values from the media alone (control)
wells. This assay is dependent on intracellular
metabolism, and absorbance will be decreased if
cell proliferation is inhibited, or if the cells are dead
or dying. All values were expressed as a percent of the
control (untreated) cells unless otherwise specified.
For prolonged incubations, drying of the samples
was avoided by the addition of sterile, distilled water
in the outer wells of microtiter plates.
Apoptosis detection
At the indicated time, the cells were harvested,
stained with the Annexin-V-Fluos (Catalog # 1 828
681, Roche Diagnostics, Indianapolis, IN) and
propidium iodide (PI) (Catalog P4170, Sigma, St.
Louis, MO) and analyzed by flow cytometry using a
Becton Dickenson Immunocytometry Systems (San
Jose, CA). CellQuest software (Becton Dickenson)
was used for the acquisition and analysis of data.
Samples were run in duplicate with 10 000 events
counted per sample. Viable cells included cells that
were negative for both annexin and PI. Viable cell
number was determined by cell counts multiplied by
the percent of viable cells.
Determination of IC50 values
The concentrations that decreased cell proliferation
by 50% (Inhibitory Concentration 50%, IC50) or by
90% (IC90 values) were determined using serial
dilutions of lovastatin (typically 500 – 0.01 mM) and
were calculated using the Graph Pad PRISM
(Version 3.0; San Diego, CA). To determine rescue
of cell proliferation from statins, plated cells were
treated with statins alone or in the presence of
mevalonate (for concentrations, see figure legends).
Plates were assayed on the specified day, with day 0
being the first day of drug exposure.
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Results
IC50 values for several AML cell lines are reported
to be 5 mM [5]. We first attempted to verify that
these concentrations were cytotoxic. After 48 h of
exposure to 4 mM of lovastatin, Trypan blue uptake
was seen in only 7.6% of HL60 cells (data not
shown). Even at a relatively high concentration of
lovastatin (50 mM), we found that only 10.7% of the
cells were Trypan blue positive after 48 h of
lovastatin exposure. In contrast, after 6 days of
culture in the presence of lovastatin, 50 mM, 82.2%
of the HL60 cells were Trypan blue positive.
Similar results were seen using U937 cell exposed
to 50 mM of lovastatin with 7.1% of U937 cells
Trypan blue positive at day 2 and 55.6% of the
U937 cells Trypan blue positive at day 6. Since
significant cell death was seen late, we examined the
time dependence and assay-dependence of statin-
induced cytotoxicity.
Time dependence of statin-induced cytotoxicity
Proliferation assays are useful for performing
replicate assays. It is well-established that statins
induce apoptosis in sensitive cells [5,11,21] and
apoptosis has been used to detect sensitivity to
statins. Therefore, we first determined whether the
time course of statin-induced cytotoxicity was the
same when assayed by the proliferation assay as
compared with cell count and apoptosis assays.
U937 cells and HL60 cells were cultured in the
presence of serial dilutions of lovastatin. The
effects on cell proliferation were determined by
both total cell counts [Figure 1(A)] and by the
proliferation assay [Figures 1(B) and 1(C)]. Using
Annexin V as a marker of apoptosis, we found that
full expression of this process is delayed for at least
4 – 5 days as judged by either the percentage of
viable cells [Figure 1(D)] or the total number of
viable cells [Figure 1(E)]. In each of these assays,
full lovastatin cytotoxic effects were delayed for 4 –
6 days, especially at lower, more clinically relevant
concentrations. Therefore, the delay in evidence of
cytotoxicity is not assay dependent when studied at
clinically relevant concentrations of lovastatin (i.e.
512 mM).
Effect of day of assay on determination of IC50
Since maximal cell death was seen after 4 – 6 days of
lovastatin exposure, it was possible that determina-
tions of cytotoxic drug concentrations at day 2 might
over-estimate the statin concentrations required to
inhibit cell growth and/or to induce cell death. To
assess the magnitude of this effect, we compared the
IC50 values as determined at day 2, with those
determined on day 6 using two cell lines, HL60 cells
and U937 cells (Figure 2). When measured by
proliferation, the IC50 for HL60 was 5.1 mM, very
similar to that found by Dimitroulakos et al. who
reported that the IC50 for HL60 cells was 5.3 mM
when measured at day 2 [5]. However, when
measured at day 6, the IC50 for HL60 cells was
1.2 mM (a 4-fold difference). The IC50 values for
U937 cells showed the same time dependence with
apparent IC50 values of 71.1 mM when measured at
day 2 and 4.5 mM at day 6 (a 15-fold difference)
[Figure 2(A)].
Ideally, a drug that is cytotoxic for AML cells
should induce cell death in 490% of cells. Using
the same experimental data as that shown in
Figure 2(A), we estimated the IC90 values for
HL60 cells and U937 cells [Figure 2(B)]. As
expected, the IC90 values for HL60 and U937 cells
were markedly higher when measured at day 2 than
at day 6. At day 2, the IC90 for HL60 cells was
46 mM while at day 6, the IC90 was 4.2 mM. The
IC90s for U937 at days 2 and 6 were 217 mM and
19.3 mM, respectively [Figure 2(B)].
Statin exposure for 48 – 72 h induces cell death in
AML cells
Although statin-induced cytotoxicity was maximal at
day 6, it was not clear whether this effect was due to
Figure 1. Time course of statin dependent effects on proliferation and AML cell viability. The time dependence of lovastatin (LST) induced
effects on proliferation and apoptosis were determined in U937 or HL60 cells. Treated samples were compared with that of untreated cells.
(N3, one example is shown for each assay.) (A) Cells counts by day of culture, at various concentrations. Cell number was determined
using a Coulter counter. Shown are total cell counts. At lower concentrations (i.e.515 mM), differences between treated and untreated cells
are best seen after at least 4 days of statin exposure. (B) Time course of changes in absorbance (MTS assay). Cell proliferation was measured
using an MTS-like colorimetric assay that reflects cellular metabolism. (C) Effects of statins during the first 2 days of culture. Cells were
plated at a concentration of 10,000 cells per well in order to look at the effects of lovastatin on proliferation during the first 2 days of drug
exposure. These results show that lovastatin did not markedly affect proliferation during the first 2 days of statin exposure, especially at the
lower concentrations studied. (D) Percentage of viable cells, by apoptosis, after lovastatin exposure, by day of culture (HL60 cells).
Percentage of cells, by day, that were negative for both PI and Annexin. (E) Viable cell number. Using the same data set as shown in 1D, the
number of viable cells was determined for each day of treatment by multiplying the number of cells as determined the Coulter counter by the
percentage of cells negative for both annexin and PI. In each assay, the cytotoxic effects of concentrations of statins in the clinically relevant
range (i.e. 5 – 12 mM) are seen only with longer duration of statin exposure.
"
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prolonged exposure to lovastatin, or due to delayed
evidence of cytotoxicity. To explore this question, we
used mevalonate to rescue cells from lovastatin.
Statins inhibit the enzyme, HMG-CoA reductase,
and thereby decrease the production of mevalonate
and its downstream metabolites. Mevalonate, when
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added to statin-containing cultures, inhibits the
cytotoxic effect of statins [11,22].
At concentrations of up to 200 mM, mevalonate
alone neither increased nor decreased the prolifera-
tion of HL60 or U937 cell lines (data not shown).
At 200 mM, mevalonate fully rescued both HL60
and U937 cells from the cytotoxic effects of a high
concentration of lovastatin (50 mM) (Figure 3). To
determine the minimum duration of lovastatin
exposure needed to induce statin cytotoxicity, we
cultured HL-60 and U937 cells in the presence of
lovastatin. After variable durations of lovastatin
exposure, mevalonate at 200 mM was added to the
cultures in an attempt to rescue the cells (Figure
4). First, we defined the minimum lovastatin
exposure time needed to induce lethality by
exposing the cells to a high concentration of
lovastatin (50 mM) and rescuing the cells with
mevalonate (200 mM) after 0, 1, 2, 4, 7, 24 or 48 h
of lovastatin exposure [Figure 4(A)]. The effects on
cell proliferation were examined at day 6. As
expected, mevalonate completely rescued cell pro-
liferation when added to the cultures at time 0.
However, after 48 h of exposure to this high
concentration of lovastatin, mevalonate was not
able to rescue either HL60 or U937 cells from
statin-induced cytotoxicity.
We next examined the time dependence of lower
concentrations of lovastatin by determining the effect
of the duration of unopposed lovastatin (before
mevalonate rescue) on the IC50 values. When
mevalonate was added after 2 days of statin exposure,
the IC50 for HL60 cells was almost the same as that
seen after 6 days of unrescued exposure to statins
[Figure 4(B)]. U937 cells required 72 h of statin
exposure before rescue in order to have an IC50 that
was similar to that seen after 6 days of statin exposure
without mevalonate rescue [Figure 4(C)].
AML cells do not recover from lovastatin exposure
after 3 days
To determine whether lovastatin induced cell death
at low concentrations or merely inhibited prolifera-
tion, we examined the viability of statin-exposed cells
using Trypan blue staining of HL60 cells at day 6,
when rescued after various durations of statin
exposure. At 12 mM of lovastatin, most of the
HL60 cells were non-viable after 48 h of statin
exposure as the number of viable cells that were
Trypan blue negative (i.e. viable) in the treated
cultures was only 10.4% that of the control cultures
[Figure 5(A)]. We also looked at the ability of
the AML cells to recover from lovastatin by incubat-
ing the cells for 72 h in the presence of serial
dilutions of lovastatin. The cells were then rescued
with mevalonate and allowed to recover for 6 days.
Despite the prolonged recovery period, the IC50
values for both U937 cells and HL60 cells were
similar to the IC50 values of the unrescued cells
[Figure 5(B)].
Discussion
High dose statins may be useful for the treatment of
AML, but the optimal drug concentration and
duration of therapy required to induce cell death in
AML cells is not known. Dimitroulakos et al.
determined the IC50 values of several AML primary
cells and cell lines and showed that six of seven of
Figure 2. Lovastatin sensitivity, as measured by IC50 and IC90 determinations at days 2 and 6. The values represent the mean+SEM
(N 3). (A) IC50 values (B) IC90 values.
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these AML cell lines had IC50 values between 1.0
and 5.3 mM when assayed after 2 days of lovastatin
exposure [3]. Our initial studies showed that most
cells appeared to be viable after 2 days of statin
exposure as determined by Trypan blue staining.
This finding was consistent with the original data
published in other studies [5,13,23]. Statins are
known to decrease cell proliferation; however, at
concentrations higher than 5 mM, statins may induce
apoptosis, resulting in cell death [24]. These initial
studies suggested that single-agent statins might not
induce cell death at clinically tolerable concentra-
tions.
As reviewed above, Phase I studies suggest that the
upper concentration of lovastatin that is clinically
tolerable is approximately 4 mM for 7 days [18] or
12 mM for 4 days [16] but these concentrations are
not tolerated when the duration of exposure is
prolonged [19]. An alternative way to improve the
therapeutic efficacy of high dose statins for the
treatment of AML might be to increase the drug
concentration while decreasing the duration of
statin exposure. However, the ability of statins to
induce cell death in AML cells after a short
exposure has not been clear. In these studies, we
demonstrate that lovastatin induces cell death in
sensitive AML lines within 72 h of exposure to
cytotoxic concentrations.
Our initial studies showed that evidence of statin-
induced effects on cell proliferation and viability
were delayed. Maximal cytotoxic effects were not
seen for at least 4 to 6 days, depending on the
particular assay (Figure 1). Delayed effects were
seen in assays of proliferation and apoptosis, as well
as traditional studies based on cell counts and
Trypan blue staining. Delays were also seen at high
concentrations of statins. The delay in evidence of
statin-induced cytotoxicity affected the determina-
tion of apparent cytotoxic drug concentrations. The
IC50 values as determined at day 2 were 4-fold
(HL60 cells) or 15-fold (U937 cells) higher than
those determined at day 6 [Figure 2(A)]. The
estimates of IC90 values showed similar discrepan-
cies, with a 10-fold increase in apparent required
concentrations of statins when the assays were
performed at day 2 as compared with day 6 [Figure
2(B)]. Thus, measurement of the IC50 at day 2 over
estimates the actual IC50 and IC90 concentrations
by ½ log or more. Most significantly, the IC50 and
IC90 values determined at day 6 predict that
lovastatin will induce cell death in AML cells at
clinically tolerable concentrations in contrast to the
less encouraging findings when these values are
determined at day 2, especially for the less sensitive
U937 cells [Figure 2(A)].
Although cytotoxicity was evident at clinically
tolerable concentrations at day 6, it was not clear
whether this increase in sensitivity at day 6 was due to
longer duration of drug exposure or due to delayed
evidence of statin effects. To distinguish the effects
of longer statin exposure from the effects of delayed
cell death, we used mevalonate to rescue cells from
statins [4]. Mevalonate alone, as a single agent,
neither increased nor decreased AML cell prolifera-
tion (Figure 3). At a high concentration of lovastatin
(50 mM), only 48 h of unopposed drug exposure
was required to block mevalonate rescue of both
HL60 and U937 cells [Figure 4(A)]. However,
50 mM lovastatin is not likely to be clinically
Figure 3. Effects of mevalonate (MLA) on proliferation in the
presence or absence of lovastatin (lov). Cells were cultured for 6
days in the presence of lovastatin (50 mM) with or without
mevalonate at the stated concentrations. Proliferation was assayed
at day 6 by the MTS assay. (N¼ 3 for each cell line) (A) HL60
Cells (B) U937 cells.
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tolerable. For this reason, we next explored the
relationships among duration of lovastatin exposure
before mevalonate rescue and the IC50 values.
These studies demonstrated that when mevalonate
rescue was delayed for 48 h [HL60 cells, Figure
4(B)] or 72 h [U937 cells, Figure 4(C)], the IC50
values were essentially the same as the IC50 values
of unrescued cells exposed to lovastatin for 6 days
[Figures 4(B) and 4(C)]. These results were not
assay dependent as similar results were seen using
Trypan blue staining of HL60 cells exposed to
clinically relevant concentrations of lovastatin [Fig-
ure 5(A)]. Therefore, although full evidence of
statin-induced cell death is delayed for 5 – 6 days,
statins induce irreversible lethal effects in AML cells
within 48 – 72 h.
Since lovastatin inhibits cell proliferation, it was
also possible that these cells were not dead but simply
had stopped proliferating and did not have time to
recover. To test this possibility, we exposed the AML
cells to lovastatin for 72 h, then rescued the cells with
mevalonate and allowed them to proliferate for a full
6 days after mevalonate rescue. Even after 6 days of
mevalonate rescue, neither HL60 cells nor U937
cells were able to resume proliferation (Figure 5).
Taken together, these results suggest that AML
cells with sensitivity similar to HL60 and U937
cells might undergo cell death at lovastatin
concentrations of 12 mM or less, and that this
effect is irreversible within 48 – 72 h of exposure to
cytotoxic concentrations of this drug. The clinical
importance of these findings is that they imply that
at least some cells will have IC50 values, or even
IC90 values, at concentrations that might be
clinically tolerable for 2 – 3 days (i.e. 12 mM).
Furthermore, statins at clinically tolerable concen-
trations do not merely inhibit cell proliferation;
rather, they induce cell death. One limitation of
our studies is that these have been performed only
in AML cell lines. Studies in primary cells are
presently ongoing; however, previous reports in-
dicate that the statin sensitivity of primary cells
corresponds well to that of AML cell lines [5].
The time dependence of statin-induced cytotoxi-
city has been previously noted as an incidental
Figure 4. Number of days of statin exposure required for maximal
statin-induced cytotoxicity. After various durations of lovastatin
exposure, mevalonate was added to the cells to rescue them from
the cytotoxic effects of statins in order to determine the minimum
duration of statin exposure needed to induce a cytotoxic effect. (A)
Duration of lovastatin exposure required at high concentrations
(50 mM). HL60 and U937 cells were cultured with 50 M
lovastatin for 0, 1, 2, 4, 7, 24 or 48 h prior to the addition of
200 mM Mevalonate. The culture was then incubated for 4
additional days and then assayed using the MTS-based prolifera-
tion assay (N3 for each cell line). (B and C): IC50 determina-
tions by day of rescue. Mevalonate was added on the indicated day
of lovastatin treatment. IC50 values were determined on day 6
(N¼3 for each cell line). (B) HL60 Cells. (C) U937 Cells.
3
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finding in AML cells [5]. In myeloma cells,
simvastatin and flustatin increase the sensitivity to
cytotoxic agents in a time-dependent manner [25].
Although statins affect activation of the MAPK
signaling pathway within 6 h, induction of caspase
3 is not seen for 48 h [26].
In vitro, a few days of lovastatin exposure
synergistically increases the sensitivity of malignant
cells to chemotherapy. This effect may be more
marked in drug-resistant cell lines [4,27].
Clinically, statins seem to be well-tolerated in
combination with cytotoxic agents as the toxicities
are non-overlapping. A Phase I trial of pravastatin,
in combination with idarubicin and cytarabine
produced encouraging responses in patients with
high-risk leukemia [28]. Van der Spek et al. treated
patients with simvastatin 15 mg/kg/day for 7 days
before chemotherapy with VAD or CHOP regi-
mens for myeloma or lymphoma, respectively, with
an overall response rate of 30% in a heavily pre-
treated population and minimal evident toxicity
[25]. Forty-eight to 72 h of lovastatin or simvasta-
tin exposure sensitized AML cells to cytarabine
[29,30, for example]. Therefore, these preliminary
clinical and laboratory studies suggest that a short
course of high dose statins can be tolerated in
combination with cytotoxic agents.
In summary, we found that the full cytotoxic effect
of lovastatin in AML cells was not seen for at least
4 – 6 days after exposure to lovastatin. Despite the
delayed evidence of cell death, lovastatin induces
irreversible lethality after 48 – 72 h of drug exposure.
These irreversible toxic effects occur at clinically
tolerable concentrations of 12 mM for both HL60
and U937 cells. In conjunction with the results of
Phase I studies, these results suggest that high-dose,
short course statins might induce cell death in AML
cells at plasma concentrations that are clinically
tolerable if high dose statin exposure is limited to
4 days. These studies also provide theoretical
support for the development of additional clinical
studies to examine the tolerability and efficacy of
high-dose, short-course statins for the treatment of
patients with AML.
Figure 5. Effect of lovastatin pre-treatment on viability at clinically
attainable concentrations. (A) Viability as assessed by Trypan blue
staining: HL60 cells were treated with 1, 3 or 12 mM lovastatin on
Day 0. Mevalonate (200 mM) was added to the cells on day 1, 2, 3,
4 or 5. The effects on viability determined on day 6 as measured by
cell counts and Trypan blue uptake. N¼2; one example is shown.
(B) Ability to recover from lovastatin after 72 h of exposure. HL60
or U937 cells were exposed to lovastatin for 72 h and then rescued
with mevalonate (200 mM). They were allowed to proliferate for an
additional 6 days. The IC50 was determined after a total of 3 days
of lovastatin exposure and 6 days of mevalonate-rescued growth,
i.e. on day 9. Two separate assays were performed and the results
for each are as shown (N¼2 for each cell line, with the individual
samples indicated by ‘‘A’’ or ‘‘B’’). For comparison purposes, the
IC50 values as determined previously are plotted (same data as
Figure 2, day 6).
3
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